---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-010269"
form_type: "8-K"
ticker: "FEED"
cik: "0001326706"
company_name: "ENvue Medical, Inc."
filed_at: "2025-03-14T23:59:59+00:00"
generated_at: "2026-05-24T18:00:19.673647+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NanoVibronix UroShield study shows 86% fewer UTIs, 70% fewer blockages, cost savings

## Summary
- 86% reduction in UTI incidence and 70% fewer catheter blockages in independent study published in Australian and New Zealand Continence Journal.
- 82.8% less bladder irrigations and 52.3% fewer catheter changes reported with UroShield use.
- Resource costs reduced by 63.5% over 5 months, easing nursing workload and lowering healthcare expenses.
- CEO Brian Murphy highlighted improved patient comfort and reduced catheter-related interventions.

## SEC filing metadata
- accession: 0001493152-25-010269
- form_type: 8-K
- ticker: FEED
- cik: 0001326706
- company_name: ENvue Medical, Inc.
- filed_at: 2025-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326706/000149315225010269/0001493152-25-010269-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326706/000149315225010269/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-010269
- JSON: https://secwatch.observer/filing/0001493152-25-010269.json
- Plain text: https://secwatch.observer/filing/0001493152-25-010269.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.